RT Journal Article
SR Electronic
T1 Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.06.21254882
DO 10.1101/2021.04.06.21254882
A1 Talia Kustin
A1 Noam Harel
A1 Uriah Finkel
A1 Shay Perchik
A1 Sheri Harari
A1 Maayan Tahor
A1 Itamar Caspi
A1 Rachel Levy
A1 Michael Leschinsky
A1 Shifra Ken Dror
A1 Galit Bergerzon
A1 Hala Gadban
A1 Faten Gadban
A1 Eti Eliassian
A1 Orit Shimron
A1 Loulou Saleh
A1 Haim Ben-Zvi
A1 Doron Amichay
A1 Anat Ben-Dor
A1 Dana Sagas
A1 Merav Strauss
A1 Yonat Shemer Avni
A1 Amit Huppert
A1 Eldad Kepten
A1 Ran D. Balicer
A1 Doron Nezer
A1 Shay Ben-Shachar
A1 Adi Stern
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2021.04.06.21254882.abstract
AB The SARS-CoV-2 pandemic has been raging for over a year, creating global detrimental impact. The BNT162b2 mRNA vaccine has demonstrated high protection levels, yet apprehension exists that several variants of concerns (VOCs) can surmount the immune defenses generated by the vaccines. Neutralization assays have revealed some reduction in neutralization of VOCs B.1.1.7 and B.1.351, but the relevance of these assays in real life remains unclear. Here, we performed a case-control study that examined whether BNT162b2 vaccinees with documented SARS-CoV-2 infection were more likely to become infected with B.1.1.7 or B.1.351 compared with unvaccinated individuals. Vaccinees infected at least a week after the second dose were disproportionally infected with B.1.351 (odds ratio of 8:1). Those infected between two weeks after the first dose and one week after the second dose, were disproportionally infected by B.1.1.7 (odds ratio of 26:10), suggesting reduced vaccine effectiveness against both VOCs under different dosage/timing conditions. Nevertheless, the B.1.351 incidence in Israel to-date remains low and vaccine effectiveness remains high against B.1.1.7, among those fully vaccinated. These results overall suggest that vaccine breakthrough infection is more frequent with both VOCs, yet a combination of mass-vaccination with two doses coupled with non-pharmaceutical interventions control and contain their spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by an ERC starting grant 852223 (RNAVirFitness), by an Israeli Science Foundation grant 3963/19, and by kind donations from the Millner and AppFlyer foundations. This study was supported in part by fellowships to TK, NH, and SH from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the CHS institutional review board (IRB #0016-21-COM2) and was exempt from the requirement for informed consent. The study was further approved by the Tel-Aviv University ethics committee (0002706-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences were uploaded to GISAID.